Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
Patients above age 18 with a first episode of immune thrombocytopenia are randomized 1:1
between 2-4 weeks of daily prednisone (1 mg/kg/d) with subsequent dose tapering (arm A) and
six 3-week cycles of pulsed dexamethasone (0.6 mg/kg/d, days 1-4; arm B). The primary
endpoint is duration of remission defined as platelets ≥50/nl.